Culverwell Anthony James 4
4 · Quoin Pharmaceuticals, Ltd. · Filed Dec 27, 2024
Insider Transaction Report
Form 4
Culverwell Anthony James
Director
Transactions
- Purchase
Series F Warrants (right to buy)
2024-12-23+100,000→ 100,000 totalExercise: $0.45From: 2024-12-23Exp: 2026-12-23→ ADS (100,000 underlying) - Purchase
Ordinary Shares
2024-12-23$0.45/sh+100,000$45,000→ 100,317 total - Purchase
Series G Warrants (right to buy)
2024-12-23+100,000→ 100,000 totalExercise: $0.45From: 2024-12-23Exp: 2029-12-24→ ADS (100,000 underlying)
Footnotes (3)
- [F1]Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.
- [F2]Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."
- [F3]The Warrants were exercisable immediately, subject to a beneficial ownership cap.